ArticleTherapeutic advances in urology2012
Mirabegron: a review of recent data and its prospects in the management of overactive bladder.
Article in Therapeutic advances in urology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 1 synthesis or guideline pooled it, 134 citations in OpenAlex.
- A Guide to Medications Inducing Salivary Gland Dysfunction, Xerostomia, and Subjective Sialorrhea: A Systematic Review Sponsored by the World Workshop on Oral Medicine VI.Drugs in R&D · 2017Pooled it
- Mirabegron nighttime versus daytime dosing for women with overactive bladder syndrome: a randomized controlled trial.Scientific reports · 2025Trial
- Chronic mirabegron treatment increases human brown fat, HDL cholesterol, and insulin sensitivity.The Journal of clinical investigation · 2020Trial
- Regulation of Human Adipose Tissue Activation, Gallbladder Size, and Bile Acid Metabolism by a β3-Adrenergic Receptor Agonist.Diabetes · 2018Trial
- Activation of human brown adipose tissue by a β3-adrenergic receptor agonist.Cell metabolism · 2015 · on this mapTrial
- Response to Boland et al. "Appraisal of the references supporting STOPP/START version 3 criteria".European geriatric medicine · 2026Article
- Therapeutic Potential of the β3-Adrenergic Receptor and Its Ligands in Cardiovascular Diseases.International journal of molecular sciences · 2025Review
- Mirabegron exhibits antibacterial and Immunomodulatory activities demonstrated by in vitro and in vivo studies.Scientific reports · 2025Article
- Eco-friendly spectrofluorimetric determination of mirabegron in human plasma and tablets: greenness and blueness assessment.BMC chemistry · 2025Article
- Thermogenic Targets for Obesity Management in the Era of Incretin-Based Therapies.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Sustainable UV approaches backed by one step extraction procedure for quantifying the newly released mirabegron and silodosin mixture in urine.Scientific reports · 2025Article
- Effect of β3-adrenergic receptor agonists on [EJNMMI research · 2025Article
- Depletion of WWP1 Increases Adrb3 Expression and Lipolysis in White Adipose Tissue of Obese Mice.International journal of molecular sciences · 2025Article
- Enantioseparation of Mirabegron Using Cyclodextrin-based Chiral Columns: High-performance Liquid Chromatography and Molecular Modeling Study.Journal of separation science · 2025Article
- Intestinal Absorption Site-Guided Development and Evaluation of Oral Disintegrating Controlled Release Tablets of Mirabegron.AAPS PharmSciTech · 2024Article
- Effect of Mirabegron in Men With Overactive Bladder and Erectile Dysfunction: A Prospective Observational Study.Cureus · 2024Article
- The β3-AR agonist BRL37344 ameliorates the main symptoms of X-linked nephrogenic diabetes insipidus in the mouse model of the disease.Journal of cellular and molecular medicine · 2024Article
- Medicinal plants and natural products for treating overactive bladder.Chinese medicine · 2024Review
- Risk of dementia associated with anticholinergic drugs for overactive bladder in adults aged ≥55 years: nested case-control study.BMJ medicine · 2024Article
- Weighing in on the role of brown adipose tissue for treatment of obesity.Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mirabegron is a novel, once-daily, orally active, first-in-class, potent β(3)-adrenoceptor agonist recently approved by Food and Drug Administration for overactive bladder therapy. Phase II studies and four large-scale phase III multinational randomized, controlled trials have supported the efficacy and tolerability of mirabegron in the clinical trial setting of patients with overactive bladder for up to 12 weeks of therapy and in the long term (12 months). The reported incidence and severity of treatment-emergent and serious adverse effects were similar to antimuscarinics, but with a more than threefold lower incidence of dry mouth compared with tolterodine. However, the effects on the cardiovascular system, pharmacokinetic interactions with other drugs, and increased incidence of new malignant events will require careful evaluation in the near future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.